Miller, Robert E <br/><br/>
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.  [electronic resource] 

 -  Molecular cancer therapeutics  Jul 2008 
 - 2160-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1535-7163 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-08-0046  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Bone Neoplasms--complications<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Docetaxel<br/>Humans<br/>Male<br/>Mice<br/>Mice, Nude<br/>Osteolysis--complications<br/>Osteoprotegerin--pharmacology<br/>Prostatic Neoplasms--pathology<br/>RANK Ligand--antagonists & inhibitors<br/>Receptors, Fc<br/>Survival Analysis<br/>Taxoids--pharmacology<br/>Tumor Burden--drug effects<br/>Whole Body Imaging<br/>Xenograft Model Antitumor Assays